Shenzhen Salubris Pharmaceuticals Co., Ltd.

    • AG·尊龙凯时

    • Ticagrelor Tablets 60mg (Taiyi),Ceftazidime for Injection(Xinlixin),Rivaroxaban Tablets,Benazepril Hydrochloride Tablets(Xindayi),Lercanidipine Hydrochloride Tablets(Xindaping)were listedin national collective drug purchase.


    • OlmesartanMedoxomil Tablets (Xindayue), Ticagrelor Tablets (Taiyi), DesloratadineTablets (Xinminting) and Pitavastatin Calcium Tablets (Xinliming) were listedin national collective drug purchase.


    • Rapamycindrug-eluting vertebral artery stent system (Maurora®) was approved by"Medical Device Registration Certificate".

    • Agreementwas signed with JT to obtain exclusive development, commercialization andsublicense rights of Enarodustat in the Chinese market.

    • FirstSalubris Recombinant Teriparatide (Xinfutai) for Injection was approved formarket.

    • Pitavastatin calcium tablets (Xinliming) approved for market

    • Bivalirudinfor Injection(Taijianing) was approved by EU GMP certificate

    • Allisartan Isoproxil Tablets (Xinlitan) won the 20th China Patent Gold Award.

    • Investment and acquisition on Biovention,Inc.

    • ClopidogrelBisulfate Tablets (Taijia) in 25mg strength was qualified by evalsuation ofgenerics consistency.

    • Take shakes in Sichuan Jinjiang Electronic Science and Technology Co., Ltd. and KingstronBio (Changshu) Co., Ltd.

    • OnDecember 29, CDE released the first batch of varieties passing the consistencyevalsuation, and Clopidogrel Bisulfate Tablets (Taijia) 75mg became the firstbatch of medicine passing evalsuation of generics consistency.

    • Allisartan Isoproxil Tablets(Xinlitan) was included in National Drug Reimbursement List.

    • Salubris Biotherapeutics, Inc. was found in the USA.

    • Salubris exclusively subsidized the “whole-hearted care” whole-course drug delivery program for patients with acute coronary syndrome (ACS).

    • Salubris acquired Alain Biotechnology (Beijing) Co., Ltd.

    • Clopidogrel Bisulfate Tablets (Taijia) won the 17th China Patent Gold Award.


    • Salubris acquired Shenzhen KYD Biomedical Technology Co., LTD


    • Salubris (Chengdu) Jinkai Biopharmaceutical Research and Development Base was joined in Salubris

    • Salubris (Suzhou) Jinmeng Biopharmaceutical Production Base was joined in Salubris.

    • ClopidogrelBisulfate Tablets(Taijia) was approved by EU GMP certificate.

    • AllisartanIsoproxil Tablets (Xinlitan) was rated as "Top 10 prescription drugs inChina 2013" at the 11th China Pharmaceutical Marketing Outstanding Forumand the Selection Conference of China's Top 10 Prescription Drugs in 2013.

    • Salubris (Pingshan) Biomedical and Pharmaceutical Preparation Industrialization Base was established.


    • Salubris (Daya Bay) Oral Preparation and Chemical APIs Base was established.

    • Salubris (Shandong) Pharmaceutical Intermediate and API Production Base was established.

    • Shenzhen Salubris Pharmaceuticals Co., Ltd. was successfully listed on Shenzhen Stock Exchange.

    • APIs Plant of Shenzhen Salubris Pharmaceuticals Co., Ltd. was established and put into production.

    • ClopidogrelBisulfate Tablets (Taijia) and Desloratadine Tablets (Xinminting) were ratedas national key new products in 2002.

    • The exclusive Clopidogrel Bisulfate Tablets（Taijia) has been put into production.

    • Pharmaceutical Plant of Shenzhen Salubris Pharmaceuticals Co., Ltd. was established and put into production.

    • Thefirst product, Azithromycin Dispersible Tablet (Xindakang), was put intoproduction.

    • On November 3, Shenzhen Salubris Pharmaceuticals Co., Ltd. was established.